Trial Search Results

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Stanford Investigator(s):


  • Drug: Exosurf
  • Drug: Survanta


Phase 2/Phase 3


Inclusion Criteria:

   - Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
   receiving assisted ventilation with 30% oxygen or more

Exclusion Criteria:

   - Less than 6 hours of age

Ages Eligible for Study

N/A - 6 Hours

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting